XORTX Therapeutics Inc.
TSXV XRTX.V
XORTX Therapeutics Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -1.41
-
XORTX Therapeutics Inc. 52-week high Price to Earnings Ratio (P/E) is -1.23 on December 20, 2024, which is 12.95% above the current Price to Earnings Ratio (P/E).
-
XORTX Therapeutics Inc. 52-week low Price to Earnings Ratio (P/E) is -9.41 on March 06, 2024, which is -565.90% below the current Price to Earnings Ratio (P/E).
-
XORTX Therapeutics Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -3.20.
| Date | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield |
|---|
| CEO | Dr. Allen Warren Davidoff Ph.D. |
| IPO Date | Nov. 5, 2021 |
| Location | Canada |
| Headquarters | 421 – 7th Avenue SW |
| Employees | 2 |
| Sector | Health Care |
| Industries | |
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Past 5 years
USD 5.75
StockViz Staff
January 15, 2025
Any question? Send us an email